hydralazine has been researched along with Body Weight in 95 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 8.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 7.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 7.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "We investigated the effects of hydralazine on renal sympathetic nerve activity in anaesthetized heart failure rats." | 7.69 | Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "The antihypertensive and tissue-protective effects of nitrendipine were studied after long-term treatment of rats with experimental hypertension." | 7.68 | Long-term protective effects of nitrendipine in experimental hypertension. ( Kazda, S; Knorr, A; Neuser, D; Seuter, F; Stasch, JP, 1991) |
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 5.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| "Hydralazine was administered at 6 and 10-14 mg kg(-1) day(-1) for lean and obese hydralazine groups, respectively." | 5.32 | Hydralazine treatment alters body composition in the rabbit model of obesity. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| "Hydralazine treatment normalized blood pressure in ANG II-infused rats." | 5.30 | Mechanisms contributing to angiotensin II regulation of body weight. ( Cassis, LA; Fettinger, MJ; Lodder, RA; Marshall, DE; Rosenbluth, B, 1998) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 4.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 3.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 3.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| " Sensitivity of VSCR control of efferent renal sympathetic nerve activity (RSNA) in SHR is restored when cardiac hypertrophy and hypertension are reduced by enalapril treatment." | 3.74 | Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats. ( Abreu, GR; Bissoli, NS; de Andrade, TU; de Melo Cabral, A; Moysés, MR, 2008) |
| " One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)." | 3.73 | Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005) |
| " Hydralazine prevented hypertension and arteriolar rarefaction in adult mice, suggesting a non-NO-dependent pathway." | 3.71 | Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. ( Besnard, S; Feletou, M; Huang, PL; Kubis, N; Lévy, BI; Silvestre, JS; Tedgui, A, 2002) |
| " After 10 weeks of treatment with benidipine (1, 3, and 5 mg/kg body weight, p." | 3.70 | Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis. ( Kawachi, H; Nakamura, T; Obata, JE; Onitsuka, M; Shimada, Y; Shimizu, F; Yoshida, Y, 2000) |
| "Although evidence has been accumulated to support a role of endothelin-1 (ET-1) in cardiac hypertrophy, details of the pathophysiological significance of ET-1 in cardiac hypertrophy remain to be elucidated." | 3.70 | Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats. ( Adachi, C; Naruse, K; Naruse, M; Seki, T; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T, 2000) |
| "We investigated the pathophysiological significance of adrenomedullin (AM) in the development of left ventricular hypertrophy (LVH)." | 3.70 | Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. ( Dohi, K; Horio, T; Kangawa, K; Matsuo, H; Morimoto, A; Nagaya, N; Nishikimi, T; Yoshihara, F, 1999) |
| "A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure." | 3.70 | Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999) |
| "We investigated the effects of hydralazine on renal sympathetic nerve activity in anaesthetized heart failure rats." | 3.69 | Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "The antihypertensive and tissue-protective effects of nitrendipine were studied after long-term treatment of rats with experimental hypertension." | 3.68 | Long-term protective effects of nitrendipine in experimental hypertension. ( Kazda, S; Knorr, A; Neuser, D; Seuter, F; Stasch, JP, 1991) |
| "To evaluate the role of glomerular hypertension, glomerular hypertrophy, glomerular lipid deposition, and plasma cholesterol levels in diabetic glomerulopathy, Munich-Wistar rats received streptozocin and daily insulin injections and were assigned to one of three groups: untreated diabetic (DMC), hydralazine-treated diabetic (DMH), and enalapril-treated diabetic (DME)." | 3.68 | Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. ( Fujihara, CK; Padilha, RM; Zatz, R, 1992) |
| "The effects of enalapril and hydralazine upon left ventricular hypertrophy in SHRSP were consistent with their respective effects upon blood pressure." | 3.68 | Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats. ( Cleary, EG; King, RA; Krishnan, R; Smith, RM, 1992) |
| "Pinacidil is a direct vasodilator with good absorption, a half-life of 2 to 4 hours, and side effects similar to those of other vasodilators." | 2.66 | A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension. ( Byyny, RL; LoVerde, ME; Mitchell, WD; Nies, AS, 1987) |
| "The incidence of preeclampsia in the randomized prophylactic antihypertensive group was statistically lower than that in the nonrandomized group (8." | 2.65 | The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies. ( Crenshaw, MC; Dorminy, JH; Gall, SA; Jelovsek, FR; Welt, SI, 1981) |
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 1.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| "High body iron levels are found in type 2 diabetes mellitus (DM)." | 1.39 | Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat. ( Akahori, H; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Tsujino, T, 2013) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| " In conclusion, our findings suggested that chronic administration of olmesartan ameliorated the endothelial dysfunction in L-NAME-treated rats." | 1.33 | Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats. ( Abe, S; Ishihara, M; Ishizawa, K; Izawa, Y; Kanematsu, Y; Kawazoe, K; Motobayashi, Y; Ohnishi, H; Tamaki, T; Tsuchiya, K, 2006) |
| "Hydralazine treatment consisted of 6 mg/kg/day and 10 to 14 mg/kg/day for LH and OH, respectively." | 1.33 | Loss of diurnal rhythms of blood pressure and heart rate caused by high-fat feeding. ( Carroll, JF; Strange, T; Thaden, JJ; Wright, AM, 2005) |
| "When hydralazine was administered to the mutant mice fed a high-salt diet, BP was reduced to 72." | 1.32 | Alterations in renal endothelial nitric oxide synthase expression by salt diet in angiotensin type-1a receptor gene knockout mice. ( Fukamizu, A; Hashimoto, T; Hirawa, N; Kihara, M; Koide, Y; Matsushita, K; Sato, K; Tamura, K; Toya, Y; Umemura, S, 2004) |
| "Hydralazine was administered at 6 and 10-14 mg kg(-1) day(-1) for lean and obese hydralazine groups, respectively." | 1.32 | Hydralazine treatment alters body composition in the rabbit model of obesity. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| "Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP." | 1.32 | Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. ( Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H, 2003) |
| "Hydralazine was the only drug to alter the lipid peroxidation level in the myocardium of SHR rats (a 28% decrease), but in WKY rats all three drugs caused significant decreases in myocardial lipid peroxidation levels." | 1.30 | Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. ( Cabell, KS; Johnson, P; Ma, L, 1997) |
| "Hydralazine treatment normalized blood pressure in ANG II-infused rats." | 1.30 | Mechanisms contributing to angiotensin II regulation of body weight. ( Cassis, LA; Fettinger, MJ; Lodder, RA; Marshall, DE; Rosenbluth, B, 1998) |
| " Here, we evaluated whether chronic administration of an NO donor, molsidomine, controlled systemic blood pressure and renal disease progression and prolonged survival in rats with renal mass reduction (RMR)." | 1.30 | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. ( Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C, 1999) |
| "Furosemide was added after the 3-week examination, and at 6 months, dogs had received furosemide for at least 4 months." | 1.29 | Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. ( Häggström, J; Hansson, K; Karlberg, BE; Kvart, C; Madej, A; Olsson, K, 1996) |
| " In SHR cells, the maximal slope conductance of the levcromakalim-evoked current, normalized by cell capacitance, was decreased, and the dose-response curve was shifted to the right compared with WKY cells." | 1.29 | Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats. ( Abe, I; Fujii, K; Fujishima, M; Nagao, T; Ohya, Y; Setoguchi, M, 1996) |
| "Treatment with captopril also reduced the development of glomerular sclerosis." | 1.29 | Effects of captopril and hydralazine on progression of adriamycin nephropathy in spontaneously hypertensive rats. ( Bogdanovic, G; Djukanovic, L; Jovanovic, D; Kartaljevic, G; Starcevic, A; Susic, D; Varagic, J, 1994) |
| " Dose-response curves of resistance arteries to ET-1 were significantly blunted in untreated hypertensive rats (maximum active tension = 2." | 1.29 | Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats. ( Deng, LY; Schiffrin, EL, 1993) |
| "Treatment with hydralazine decreased blood pressure in a similar way as trandolapril but did not affect either LV weight or LV Ang II." | 1.28 | Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. ( Higaki, J; Higashimori, K; Mikami, H; Nagano, M; Nagano, N; Nakamura, F; Ogihara, T, 1992) |
| "The anipamil-treated group exhibited significantly greater protection of renal function than did the hydralazine-treated group for the same level of blood pressure control." | 1.28 | Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. ( Chan, L; Jarusiripipat, C; Schrier, RW; Shapiro, JI, 1992) |
| "Hydralazine tended to lower LV MCVR per 100 g in both strains despite its tendency to increase ventricular mass." | 1.28 | Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. ( Canby, CA; Tomanek, RJ, 1989) |
| " Daily oral dosing of hydralazine (2 mg/kg/day) for 14 weeks had little or no effect on SBP, but potentiated the antihypertensive effect of SA446." | 1.27 | [Antihypertensive effects of SA446, hydralazine and the combination on renal hypertensive rats and spontaneously hypertensive rats by long-term treatment]. ( Iso, T; Nakata, K; Nishimura, K; Takada, T; Yamauchi, H, 1986) |
| "Treatment with hydralazine did not affect left ventricular weight and caused a small increase in the weight of the right ventricle." | 1.27 | Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. ( Leenen, FH; Tsoporis, J, 1988) |
| "Phentolamine (10(-6) M) pretreatment had no effect on the ouabain-induced contraction but partially suppressed it in both SHR and WKY aortas when diltiazem (10(-5) M) was also added." | 1.27 | Ouabain-induced contraction of vascular smooth muscle in spontaneously hypertensive rats and the effect of hydralazine. ( Iwasaki, T; Kawai, Y; Miyata, S; Morita, S; Nagai, K, 1988) |
| "The treatment of both hyperlipidemia and hypertension appeared to be more effective than the treatment of hyperlipidemia, alone." | 1.26 | Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta. ( Hollander, W; Kirkpatrick, B; Madoff, I; Paddock, J, 1976) |
| "Hydralazine treatment of young SHR partially prevented the increase of both alkaline phosphatase activity and blood pressure that develops with age." | 1.26 | Relationship between blood pressure of spontaneously hypertensive rats and alterations in membrane properties of mesenteric arteries. ( Daniel, EE; Janis, RA; Wei, JW, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (35.79) | 18.7374 |
| 1990's | 27 (28.42) | 18.2507 |
| 2000's | 28 (29.47) | 29.6817 |
| 2010's | 4 (4.21) | 24.3611 |
| 2020's | 2 (2.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, Y | 1 |
| Naito, H | 1 |
| Kitamori, K | 1 |
| Hashimoto, S | 1 |
| Asano, T | 1 |
| Nakajima, T | 1 |
| Larkin, BP | 1 |
| Saad, S | 1 |
| Glastras, SJ | 1 |
| Nguyen, LT | 1 |
| Hou, M | 1 |
| Chen, H | 1 |
| Wang, R | 1 |
| Pollock, CA | 1 |
| Matsumoto, M | 1 |
| Sasaki, N | 1 |
| Tsujino, T | 1 |
| Akahori, H | 1 |
| Naito, Y | 1 |
| Masuyama, T | 1 |
| Katayama, IA | 1 |
| Pereira, RC | 1 |
| Dopona, EP | 1 |
| Shimizu, MH | 1 |
| Furukawa, LN | 1 |
| Oliveira, IB | 1 |
| Heimann, JC | 1 |
| Rodrigues, SF | 1 |
| de Oliveira, MA | 1 |
| dos Santos, RA | 1 |
| Soares, AG | 1 |
| de Cássia Tostes, R | 1 |
| Carvalho, MH | 1 |
| Fortes, ZB | 1 |
| de Andrade, TU | 1 |
| Abreu, GR | 1 |
| Moysés, MR | 1 |
| de Melo Cabral, A | 1 |
| Bissoli, NS | 1 |
| Bagnost, T | 2 |
| Berthelot, A | 2 |
| Alvergnas, M | 1 |
| Miguet-Alfonsi, C | 1 |
| André, C | 2 |
| Guillaume, Y | 2 |
| Demougeot, C | 2 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 2 |
| Fukuda, M | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Sofue, T | 1 |
| Kiyomoto, H | 2 |
| Kobori, H | 2 |
| Urushihara, M | 1 |
| Nishijima, Y | 1 |
| Kaifu, K | 1 |
| Hara, T | 1 |
| Matsumoto, S | 1 |
| Ichimura, A | 1 |
| Ohsaki, H | 1 |
| Hitomi, H | 1 |
| Kawachi, H | 3 |
| Hayden, MR | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Ito, S | 1 |
| Kohno, M | 2 |
| Nishiyama, A | 2 |
| Grisk, O | 1 |
| Rose, HJ | 1 |
| Lorenz, G | 1 |
| Rettig, R | 1 |
| Sanada, S | 1 |
| Node, K | 1 |
| Asanuma, H | 1 |
| Ogita, H | 1 |
| Takashima, S | 1 |
| Minamino, T | 1 |
| Asakura, M | 1 |
| Liao, Y | 1 |
| Ogai, A | 1 |
| Kim, J | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Nangaku, M | 1 |
| Miyata, T | 1 |
| Sada, T | 2 |
| Mizuno, M | 1 |
| Inagi, R | 1 |
| Ueda, Y | 1 |
| Ishikawa, N | 1 |
| Yuzawa, H | 1 |
| Koike, H | 2 |
| van Ypersele de Strihou, C | 1 |
| Kurokawa, K | 1 |
| DAVIS, CD | 1 |
| Virdis, A | 1 |
| Neves, MF | 1 |
| Amiri, F | 1 |
| Touyz, RM | 1 |
| Schiffrin, EL | 2 |
| Dikow, R | 1 |
| Kihm, LP | 1 |
| Zeier, M | 1 |
| Kapitza, J | 1 |
| Törnig, J | 1 |
| Amann, K | 2 |
| Tiefenbacher, C | 1 |
| Ritz, E | 2 |
| Carroll, JF | 2 |
| King, JW | 1 |
| Cohen, JS | 1 |
| Goossens, GH | 1 |
| Blaak, EE | 1 |
| Saris, WH | 1 |
| van Baak, MA | 1 |
| Sato, K | 1 |
| Kihara, M | 1 |
| Hashimoto, T | 1 |
| Matsushita, K | 1 |
| Koide, Y | 1 |
| Tamura, K | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Fukamizu, A | 1 |
| Umemura, S | 1 |
| Nagai, Y | 1 |
| Yao, L | 1 |
| Miyata, K | 1 |
| Ozawa, Y | 1 |
| Miyatake, A | 1 |
| Yukimura, T | 1 |
| Shokoji, T | 1 |
| Kimura, S | 2 |
| Abe, Y | 1 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Shimizu, F | 2 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Loufrani, L | 2 |
| Henrion, D | 2 |
| Thaden, JJ | 1 |
| Wright, AM | 1 |
| Strange, T | 1 |
| Zhao, Y | 1 |
| Bell, D | 1 |
| Smith, LR | 1 |
| Zhao, L | 1 |
| Devine, AB | 1 |
| McHenry, EM | 1 |
| Nicholls, DP | 1 |
| McDermott, BJ | 1 |
| Kanematsu, Y | 1 |
| Tsuchiya, K | 1 |
| Ohnishi, H | 1 |
| Motobayashi, Y | 1 |
| Izawa, Y | 1 |
| Ishihara, M | 2 |
| Ishizawa, K | 1 |
| Abe, S | 1 |
| Kawazoe, K | 1 |
| Tamaki, T | 2 |
| Lebel, M | 1 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Larivière, R | 1 |
| Prigent-Tessier, A | 1 |
| Bouhaddi, M | 1 |
| Marie, C | 1 |
| Suganuma, E | 1 |
| Babaev, VR | 1 |
| Motojima, M | 1 |
| Zuo, Y | 1 |
| Ayabe, N | 1 |
| Fogo, AB | 1 |
| Ichikawa, I | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Kon, V | 1 |
| Hilliker, KS | 1 |
| Roth, RA | 1 |
| Bing, OH | 1 |
| Sen, S | 1 |
| Conrad, CH | 1 |
| Brooks, WW | 1 |
| Limas, C | 1 |
| Westrum, B | 1 |
| Limas, CJ | 1 |
| Johnson, BF | 1 |
| Black, HR | 1 |
| Beckner, R | 1 |
| Weiner, B | 1 |
| Angeletti, F | 1 |
| Sinaiko, AR | 1 |
| Cooper, MJ | 1 |
| Mirkin, BL | 1 |
| Franciosa, JA | 2 |
| Weber, KT | 1 |
| Levine, TB | 1 |
| Kinasewitz, GT | 1 |
| Janicki, JS | 1 |
| West, J | 1 |
| Henis, MM | 1 |
| Cohn, JN | 2 |
| Moore, MA | 1 |
| Freis, ED | 3 |
| Notargiacomo, A | 1 |
| Burris, JF | 1 |
| Welt, SI | 1 |
| Dorminy, JH | 1 |
| Jelovsek, FR | 1 |
| Crenshaw, MC | 1 |
| Gall, SA | 1 |
| Boor, PJ | 1 |
| Nelson, TJ | 1 |
| Pierpont, GL | 1 |
| Brown, DC | 1 |
| Neusüss, R | 1 |
| Irzyniec, T | 1 |
| Wiest, G | 1 |
| Mall, G | 1 |
| Deng, LY | 1 |
| Dunnett, CW | 1 |
| Tamhane, AC | 1 |
| Djukanovic, L | 1 |
| Susic, D | 1 |
| Jovanovic, D | 2 |
| Varagic, J | 1 |
| Starcevic, A | 1 |
| Kartaljevic, G | 1 |
| Bogdanovic, G | 1 |
| O'Brien, RC | 1 |
| Cooper, ME | 1 |
| Jerums, G | 1 |
| Doyle, AE | 1 |
| Ohya, Y | 1 |
| Setoguchi, M | 1 |
| Fujii, K | 2 |
| Nagao, T | 1 |
| Abe, I | 3 |
| Fujishima, M | 2 |
| Brink, M | 1 |
| Wellen, J | 1 |
| Delafontaine, P | 1 |
| Reddy, DS | 1 |
| Singh, M | 1 |
| Ghosh, S | 1 |
| Ganguly, NK | 1 |
| Häggström, J | 1 |
| Hansson, K | 1 |
| Karlberg, BE | 1 |
| Kvart, C | 1 |
| Madej, A | 1 |
| Olsson, K | 1 |
| Cabell, KS | 1 |
| Ma, L | 1 |
| Johnson, P | 1 |
| Norton, GR | 2 |
| Tsotetsi, J | 1 |
| Trifunovic, B | 1 |
| Hartford, C | 1 |
| Candy, GP | 1 |
| Woodiwiss, AJ | 2 |
| Zhang, W | 1 |
| Sun, X | 1 |
| Zhao, X | 1 |
| Thorén, P | 1 |
| Hedner, T | 1 |
| Cassis, LA | 1 |
| Marshall, DE | 1 |
| Fettinger, MJ | 1 |
| Rosenbluth, B | 1 |
| Lodder, RA | 1 |
| Casellas, D | 1 |
| Benahmed, S | 1 |
| Artuso, A | 1 |
| Jover, B | 1 |
| Wang, DH | 1 |
| Li, J | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Noris, M | 1 |
| Corna, D | 1 |
| Benedetti, G | 1 |
| Bruzzi, I | 1 |
| Todeschini, M | 1 |
| Remuzzi, G | 1 |
| Morimoto, A | 1 |
| Nishikimi, T | 1 |
| Yoshihara, F | 1 |
| Horio, T | 1 |
| Nagaya, N | 1 |
| Matsuo, H | 1 |
| Dohi, K | 1 |
| Kangawa, K | 1 |
| Goto, K | 1 |
| Onaka, U | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Adachi, C | 1 |
| Seki, T | 1 |
| Yoshimoto, T | 1 |
| Takagi, S | 1 |
| Naruse, K | 1 |
| Takano, K | 1 |
| Obata, JE | 1 |
| Onitsuka, M | 1 |
| Shimada, Y | 1 |
| Yoshida, Y | 1 |
| Lin, Y | 1 |
| Tsuchihashi, T | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Koenen, C | 1 |
| Lang, C | 1 |
| Kempe, HP | 1 |
| Werle, E | 1 |
| Hasslacher, C | 1 |
| Tsotetsi, OJ | 1 |
| Netjhardt, M | 1 |
| Qubu, D | 1 |
| Brooksbank, R | 1 |
| Kubis, N | 2 |
| Besnard, S | 1 |
| Silvestre, JS | 1 |
| Feletou, M | 1 |
| Huang, PL | 1 |
| Lévy, BI | 2 |
| Tedgui, A | 1 |
| Gorny, D | 1 |
| Wei, JW | 1 |
| Janis, RA | 1 |
| Daniel, EE | 1 |
| Onodera, T | 1 |
| Takayama, S | 1 |
| Yamada, A | 1 |
| Ono, Y | 1 |
| Akimoto, T | 1 |
| Hollander, W | 1 |
| Madoff, I | 1 |
| Paddock, J | 1 |
| Kirkpatrick, B | 1 |
| Tanaka, K | 1 |
| Fukiyama, K | 1 |
| Kumamoto, K | 1 |
| Yamamoto, Y | 1 |
| Oniki, H | 1 |
| Omae, T | 1 |
| Ragan, D | 2 |
| King, RA | 1 |
| Smith, RM | 1 |
| Krishnan, R | 1 |
| Cleary, EG | 1 |
| Grichois, ML | 1 |
| Blanc, J | 1 |
| Deckert, V | 1 |
| Elghozi, JL | 1 |
| Yuan, B | 1 |
| Leenen, FH | 2 |
| Nagano, M | 1 |
| Higaki, J | 1 |
| Nakamura, F | 1 |
| Higashimori, K | 1 |
| Nagano, N | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Fujihara, CK | 1 |
| Padilha, RM | 1 |
| Zatz, R | 1 |
| Okamoto, K | 1 |
| Ohta, Y | 1 |
| Chikugo, T | 1 |
| Shiokawa, H | 1 |
| Morita, N | 1 |
| Knorr, A | 1 |
| Kazda, S | 1 |
| Neuser, D | 1 |
| Stasch, JP | 1 |
| Seuter, F | 1 |
| Jarusiripipat, C | 1 |
| Chan, L | 1 |
| Shapiro, JI | 1 |
| Schrier, RW | 1 |
| Kimura, K | 1 |
| Tojo, A | 1 |
| Matsuoka, H | 1 |
| Sugimoto, T | 1 |
| Canby, CA | 2 |
| Tomanek, RJ | 2 |
| Fukui, K | 1 |
| Iwao, H | 1 |
| Nakamura, A | 1 |
| Yamamoto, A | 1 |
| Shoji, T | 1 |
| Aki, Y | 1 |
| Hasui, K | 1 |
| Ohkubo, H | 1 |
| Pettinger, WA | 1 |
| Mitchell, HC | 1 |
| Lee, HC | 1 |
| Redman, HC | 1 |
| Tanaka, S | 1 |
| Shibamura, S | 1 |
| Sekiguchi, F | 1 |
| Hirohashi, M | 1 |
| Shirasaki, Y | 1 |
| Akashi, A | 1 |
| Oda, T | 1 |
| Iijima, Y | 1 |
| Nishino, H | 1 |
| Oizumi, K | 1 |
| Tsoporis, J | 1 |
| Feld, LG | 1 |
| Noble, B | 1 |
| Springate, JE | 1 |
| Feldman, MJ | 1 |
| Van Liew, JB | 1 |
| Michel, JB | 1 |
| Dussaule, JC | 1 |
| Choudat, L | 1 |
| Auzan, C | 1 |
| Nochy, D | 1 |
| Corvol, P | 1 |
| Menard, J | 1 |
| Morita, S | 1 |
| Iwasaki, T | 1 |
| Nagai, K | 1 |
| Miyata, S | 1 |
| Kawai, Y | 1 |
| Byyny, RL | 1 |
| Nies, AS | 1 |
| LoVerde, ME | 1 |
| Mitchell, WD | 1 |
| Mesfin, GM | 1 |
| Shawaryn, GG | 1 |
| Higgins, MJ | 1 |
| Nakata, K | 1 |
| Nishimura, K | 1 |
| Takada, T | 1 |
| Yamauchi, H | 1 |
| Iso, T | 1 |
| Gottlieb, TB | 1 |
| Katz, FH | 1 |
| Chidsey, CA | 1 |
| Pillsbury, H | 1 |
| Mathews, M | 1 |
| Aagaard, GN | 1 |
| Ringleb, D | 1 |
| Grundner, HG | 1 |
| Krieg, R | 1 |
| Steckenmesser, R | 1 |
| Vertes, V | 1 |
| Cangiano, JL | 1 |
| Berman, LB | 1 |
| Gould, A | 1 |
7 trials available for hydralazine and Body Weight
| Article | Year |
|---|---|
Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects.
Topics: Adipose Tissue; Angiotensin II; Body Weight; Central Nervous System Depressants; Drug Interactions; | 2004 |
A comparison of minoxidil and hydralazine in non-azotemic hypertensives.
Topics: Adult; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hydralazine; Hypertension; Male; Mid | 1983 |
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Exercise Te | 1982 |
The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies.
Topics: Adult; Antihypertensive Agents; Birth Weight; Blood Pressure; Body Weight; Female; Humans; Hydralazi | 1981 |
Effect of hydralazine on renal failure in patients with congestive heart failure.
Topics: Aged; Blood Pressure; Body Weight; Creatinine; Heart Failure; Heart Rate; Humans; Hydralazine; Kidne | 1980 |
Pseudo renal artery stenosis (PRAS) syndrome.
Topics: Angiography; Blood Pressure; Body Weight; Creatinine; Double-Blind Method; Enalapril; Humans; Hydral | 1989 |
A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Dou | 1987 |
88 other studies available for hydralazine and Body Weight
| Article | Year |
|---|---|
The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive Agents; Blood Pre | 2020 |
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi | 2021 |
Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic N | 2013 |
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body | 2014 |
Hydralazine reduces leukocyte migration through different mechanisms in spontaneously hypertensive and normotensive rats.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Bod | 2008 |
Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Baroreflex; Body Weight; Cardiomegaly; Enalapril; Heart; Hemodynam | 2008 |
Misregulation of the arginase pathway in tissues of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arginase; Blood Pressure; Body Weight; Brain; Enzyme Activation; H | 2009 |
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Experiment | 2010 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucos | 2012 |
Sympathetic-renal interaction in chronic arterial pressure control.
Topics: Animals; Animals, Newborn; Arteriosclerosis; Blood Pressure; Body Weight; Creatinine; Crosses, Genet | 2002 |
Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Body Weight; Cardiomegaly; Glyburide; Hydralazine; | 2002 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mel | 2003 |
A SYSTEMATIC APPROACH TO THE THERAPY OF SEVERE PRE-ECLAMPSIA AND ECLAMPSIA.
Topics: Abortion, Therapeutic; Anesthesia; Anesthesia, Obstetrical; Anticonvulsants; Antihypertensive Agents | 1963 |
Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice.
Topics: Acetophenones; Angiotensin II; Animals; Blood Pressure; Body Weight; Collagen; Endothelium, Vascular | 2004 |
Increased infarct size in uremic rats: reduced ischemia tolerance?
Topics: Animals; Body Weight; Coronary Vessels; Heart Ventricles; Hydralazine; Imidazoles; Ischemia; Male; M | 2004 |
Hydralazine treatment alters body composition in the rabbit model of obesity.
Topics: Adipose Tissue; Animals; Body Composition; Body Water; Body Weight; Disease Models, Animal; Eating; | 2004 |
Alterations in renal endothelial nitric oxide synthase expression by salt diet in angiotensin type-1a receptor gene knockout mice.
Topics: Animals; Blotting, Western; Body Weight; Hydralazine; Immunohistochemistry; Kidney; Mice; Mice, Knoc | 2004 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy | 2005 |
Vasodilator treatment with hydralazine increases blood flow in mdx mice resistance arteries without vascular wall remodelling or endothelium function improvement.
Topics: Acetylcholine; Animals; Blood Flow Velocity; Blood Pressure; Body Weight; Calcium; Dystrophin; Endot | 2005 |
Loss of diurnal rhythms of blood pressure and heart rate caused by high-fat feeding.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Circadian Rhythm; Dietary Fats; Femal | 2005 |
Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
Topics: Adrenomedullin; Animals; Body Weight; Hydralazine; Hydrochlorothiazide; Hypertension; Intracellular | 2006 |
Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weig | 2006 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Time course of vascular arginase expression and activity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Arginase; Arginine; Blood Pressure; Body Weight; | 2007 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
Topics: Animals; Body Weight; Cardiomegaly; Dexamethasone; Heart Diseases; Hydralazine; L-Lactate Dehydrogen | 1984 |
Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment.
Topics: Animals; Body Weight; Cardiomegaly; Collagen; Guanethidine; Heart Failure; Hydralazine; Hypertension | 1984 |
Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Body Weight; Captopril; Cardiovascular System; Endothelium; Heart Ve | 1984 |
Effect of neonatal sympathectomy with 6-hydroxydopamine on reactivity of the renin-angiotensin system in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Animals, Newborn; Blood Pressure; Body Weight; Female; Hydralazine; Hydroxy | 1980 |
Step-care approach to improving hypertensive patient compliance.
Topics: Benzothiadiazines; Body Weight; Diet, Sodium-Restricted; Diuretics; Family; Hospitalization; Humans; | 1982 |
Comparative antihypertensive effects of a diuretic, reserpine, and hydralazine in the spontaneously hypertensive rat.
Topics: Animals; Body Weight; Disease Models, Animal; Female; Furosemide; Hydralazine; Hypertension; Intesti | 1981 |
Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase.
Topics: Allylamine; Amines; Animals; Body Weight; Brain; Drinking; Heart; Hydralazine; Liver; Male; Monoamin | 1980 |
Changes of vascular architecture independent of blood pressure in experimental uremia.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Blood Vessels; Body Weight; Capillaries; Furosemide; Hydr | 1995 |
Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arginine Vasopressin; Blood Pressure; Body Weight; Cilazapril; Dos | 1993 |
Step-up multiple testing of parameters with unequally correlated estimates.
Topics: Animals; Biometry; Body Weight; Captopril; Cardiovascular Physiological Phenomena; Cardiovascular Sy | 1995 |
Effects of captopril and hydralazine on progression of adriamycin nephropathy in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Captopril; Doxorubicin; Female; Glomerulonephritis; Hematocrit | 1994 |
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressu | 1993 |
Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats.
Topics: Animals; Benzopyrans; Blood Pressure; Body Weight; Cromakalim; Dose-Response Relationship, Drug; Gly | 1996 |
Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1996 |
Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Blood Pressure; Body Weight; Ca | 1996 |
Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Dog Dis | 1996 |
Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Enzyme Activation; Heart; | 1997 |
Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Body Weight; Captopril; Collagen; Cross-Linking Reagents; Diastole | 1997 |
Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Coronary Vessels; Heart Failure; Hear | 1997 |
Mechanisms contributing to angiotensin II regulation of body weight.
Topics: Adipose Tissue; Angiotensin II; Animals; Blood Pressure; Body Temperature; Body Weight; Dose-Respons | 1998 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel | 1999 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease | 1999 |
Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats.
Topics: Adrenomedullin; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction.
Topics: Acetylcholine; Administration, Oral; Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors | 2000 |
Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Endothelin-1; Hydralazi | 2000 |
Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis.
Topics: Actins; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Creatinine; Dihydropyridines | 2000 |
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2001 |
The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats.
Topics: Acetylglucosaminidase; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressur | 2000 |
Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Collagen; Heart Failure; Heart Ventri | 2001 |
Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme.
Topics: Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Capillaries; Disease Mode | 2002 |
Chronic hydralazine improves flow (shear stress)-induced endothelium-dependent dilation in mouse mesenteric resistance arteries in vitro.
Topics: Acetylcholine; Animals; Blood Flow Velocity; Body Weight; Cardiovascular Agents; Dose-Response Relat | 2002 |
Relationship between blood pressure of spontaneously hypertensive rats and alterations in membrane properties of mesenteric arteries.
Topics: Adenosine Triphosphatases; Alkaline Phosphatase; Animals; Blood Pressure; Body Weight; Calcium; Cell | 1977 |
Toxicological studies of 1-[2-(1,3-dimethyl-2-butenylidene)-hydrazino]-phthalazine, a new antihypertensive drug, in mice and rats.
Topics: Anemia; Animals; Body Weight; Dose-Response Relationship, Drug; Female; Hydralazine; Lethal Dose 50; | 1978 |
Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta.
Topics: Animals; Aortic Coarctation; Arteriosclerosis; Blood Pressure; Body Weight; Cholesterol, Dietary; Co | 1976 |
Relationship between plasma renin activity and blood pressure response to antihypertensive agents. A proposal for management of essential and renal hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Weight; Furosemide; Humans; Hydralazine; Hypert | 1975 |
Effect of treatment on longevity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Chlorothiazide; Female; Hydralazine; Hypertension; Longevity; | 1975 |
Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; DNA; Elastin; Enalapril; Heart Ventricles; Hydralazine; Hypert | 1992 |
Differential effects of enalapril and hydralazine on short-term variability of blood pressure and heart rate in rats.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Drinking Behavior; Enalapril; Heart Rate; Hydr | 1992 |
Chronic arterial vasodilation, central hemodynamics, and cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Arteries; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Drinking; Heart Rate; | 1992 |
Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Card | 1992 |
Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy.
Topics: Albuminuria; Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; | 1992 |
Chronic treatment with captopril, SQ29,852, hydralazine and a 33% fish meal diet in malignant stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Captopril; Cerebrova | 1991 |
Long-term protective effects of nitrendipine in experimental hypertension.
Topics: Animals; Arteriosclerosis; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Endothelins; Hydr | 1991 |
Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Hydralazine; Kidney; Male; Nephrecto | 1992 |
Renal arteriolar diameters in spontaneously hypertensive rats. Vascular cast study.
Topics: Aging; Animals; Arterioles; Blood Pressure; Body Weight; Captopril; Hydralazine; Hypertension; Kidne | 1991 |
Regression of ventricular hypertrophy abolishes cardiocyte vulnerability to acute hypoxia.
Topics: Animals; Blood Gas Analysis; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Heart; Hemodynami | 1990 |
Captopril and hydralazine suppress atrial natriuretic peptide (ANP) gene expression in the ventricles of spontaneously hypertensive rat.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Captopril; Gene Expression Regulati | 1989 |
Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy.
Topics: Animals; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Coronary Circulation; Heart; Hydralaz | 1989 |
[The effect of an antihypertensive drug budralazine on cerebrovascular lesions in salt-loaded SHR].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Brain; Cerebrovascular Disorders; Hyd | 1989 |
Effects of chronic treatment with a novel angiotensin converting enzyme inhibitor, CS622, and a vasodilator, hydralazine, on atrial natriuretic factor (ANF) in spontaneously hypertensive rats (SHR).
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Pressure; Body W | 1988 |
Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.
Topics: Animals; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; Epinephrine; Heart; Heart Rate; He | 1988 |
Dietary protein restriction and renal injury in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorothiazide; Dietary Proteins; Glo | 1989 |
Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Clonidine; Dihydrala | 1986 |
Ouabain-induced contraction of vascular smooth muscle in spontaneously hypertensive rats and the effect of hydralazine.
Topics: Aging; Animals; Blood Pressure; Body Weight; Calcium; Calcium Radioisotopes; Hydralazine; Hypertensi | 1988 |
Cardiovascular alterations in dogs treated with hydralazine.
Topics: Animals; Blood Chemical Analysis; Body Weight; Dogs; Heart; Heart Rate; Hemorrhage; Hydralazine; Mal | 1987 |
[Antihypertensive effects of SA446, hydralazine and the combination on renal hypertensive rats and spontaneously hypertensive rats by long-term treatment].
Topics: 3-Mercaptopropionic Acid; Animals; Antihypertensive Agents; Body Weight; Diuresis; Drinking; Drug Th | 1986 |
Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Body Weight; Cardiac Output; Female; Fu | 1972 |
Alteration of the course of hypertension in the spontaneously hypertensive rat.
Topics: Aging; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorothiazide; Environment; E | 1972 |
Clinical pharmacology and therapeutics.
Topics: Age Factors; Aged; Analgesics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents | 1972 |
[Studies on the radio-cystostatic combination therapy. 5. Syncytostatic studies on 5-fluorouracil, Natulan and Proresid].
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Drug Synergism; Fluorouracil; Hydralazin | 1969 |
Hypertension in end-stage renal disease.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Chronic | 1969 |